Approaching the threshold for predicting preeclampsia: monitoring angiogenic balance during pregnancy.

C. Banek,J. Gilbert

DOI: https://doi.org/10.1161/HYPERTENSIONAHA.111.175992

IF: 9.8968

2011-11-01

Hypertension

Abstract:See related article, pp 859-866 Recent years have seen considerable advances in the identification of biomarkers related to the development of preeclampsia.1–4 Elegant translational studies reported by Maynard et al3 and Venkatesha et al4 from the Karumanchi laboratory clearly demonstrated that the antiangiogenic factors soluble Fms-like tyrosine kinase 1 (sFlt-1; a vascular endothelial growth factor antagonist) and soluble endoglin (a transforming growth factor-β antagonist) play important roles in the pathophysiology of preeclampsia. In the following years, additional progress has been made with respect to our understanding of the mechanisms underlying the role of antiangiogenic factors in the pathophysiology of preeclampsia.2–6 Viewed in concert, these studies have clearly established the importance of angiogenic balance in the maintenance of cardiovascular function in normal pregnancy. Despite marked progress toward these ends, the translation of these findings into clinically useful paradigms has moved at a much slower pace. In lieu of the development of novel treatments for preeclampsia, much current attention has been paid to determining the usefulness of these biomarkers for identification of patients who will go on to develop preeclampsia. Indeed, this is an important endeavor for several reasons, not the least of which is that early identification of preeclamptic patients is a high yield objective for enhancing the management and treatment of this devastating disorder. Moreover, the use of angiogenic markers may be helpful in discriminating patients with preeclampsia from those …